“Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s282. https://doi.org/10.25251/skin.7.supp.282.